Cargando…

Health-related quality of life in T1DM patients after high-dose cholecalciferol supplementation: data from a pilot clinical trial

BACKGROUND: Type 1 Diabetes Mellitus (T1DM) impacts health-related quality of life (HRQoL). Cross-sectional studies suggest that low levels of vitamin D (VD) may impair HRQoL, however, the effect of VD supplementation on quality of life in T1DM patients has not yet been clarified. Our study evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: de Souza, Ana Carolina Contente Braga, de Oliveira, Maria Clara Neres Iunes, de Lemos, Gabriela Nascimento, da Silva, Emanuele Rocha, de Souza, Ícaro José Araújo, da Silva, Wanderson Maia, de Alcântara, Angélica Leite, Said, Nivin Mazen, de Moraes, Lorena Vilhena, Neto, João Felício Abrahão, dos Passos, Simone Rodrigues, Monteiro, Ádria Aline Alves, de Queiroz, Natércia Neves Marques, de Melo, Franciane Trindade Cunha, Felício, Karem Miléo, de Souza D’Albuquerque Silva, Lilian, Gomes, Daniela Lopes, Mourão, Neyla Arroyo Lara, Piani, Pedro Paulo Freire, Lobato, Isabel Jane Campos, Felício, João Soares
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959789/
https://www.ncbi.nlm.nih.gov/pubmed/35346321
http://dx.doi.org/10.1186/s13098-022-00817-w
_version_ 1784677237779333120
author de Souza, Ana Carolina Contente Braga
de Oliveira, Maria Clara Neres Iunes
de Lemos, Gabriela Nascimento
da Silva, Emanuele Rocha
de Souza, Ícaro José Araújo
da Silva, Wanderson Maia
de Alcântara, Angélica Leite
Said, Nivin Mazen
de Moraes, Lorena Vilhena
Neto, João Felício Abrahão
dos Passos, Simone Rodrigues
Monteiro, Ádria Aline Alves
de Queiroz, Natércia Neves Marques
de Melo, Franciane Trindade Cunha
Felício, Karem Miléo
de Souza D’Albuquerque Silva, Lilian
Gomes, Daniela Lopes
Mourão, Neyla Arroyo Lara
Piani, Pedro Paulo Freire
Lobato, Isabel Jane Campos
Felício, João Soares
author_facet de Souza, Ana Carolina Contente Braga
de Oliveira, Maria Clara Neres Iunes
de Lemos, Gabriela Nascimento
da Silva, Emanuele Rocha
de Souza, Ícaro José Araújo
da Silva, Wanderson Maia
de Alcântara, Angélica Leite
Said, Nivin Mazen
de Moraes, Lorena Vilhena
Neto, João Felício Abrahão
dos Passos, Simone Rodrigues
Monteiro, Ádria Aline Alves
de Queiroz, Natércia Neves Marques
de Melo, Franciane Trindade Cunha
Felício, Karem Miléo
de Souza D’Albuquerque Silva, Lilian
Gomes, Daniela Lopes
Mourão, Neyla Arroyo Lara
Piani, Pedro Paulo Freire
Lobato, Isabel Jane Campos
Felício, João Soares
author_sort de Souza, Ana Carolina Contente Braga
collection PubMed
description BACKGROUND: Type 1 Diabetes Mellitus (T1DM) impacts health-related quality of life (HRQoL). Cross-sectional studies suggest that low levels of vitamin D (VD) may impair HRQoL, however, the effect of VD supplementation on quality of life in T1DM patients has not yet been clarified. Our study evaluated the effects of high-dose VD supplementation on HRQoL in T1DM. METHODS: We performed a prospective study with 64 patients receiving cholecalciferol (4000 IU/day for patients with 25-OH-vitamin D [25(OH)D] between 30 and 60 ng/mL, and 10,000 IU/day for those with 25(OH)D below 30 ng/mL) for 12 weeks, as part of a research protocol. HRQoL was assessed with EuroQol instruments (EQ-5D and EQ-VAS). RESULTS: There was an improvement in global EQ-5D index, and analysing specifically the EQ-5D domains, we observed an improvement in mobility (1.3 ± 0.6 versus 1.1 ± 0.3, p < 0.01). Evaluating possible outcome influencing variables, we detected a reduction in albuminuria at the end of the trial, without changes in BMI, lipids, blood pressure, glycemic control and insulin doses. We found correlations between final albuminuria and the dimensions: mobility (r = 0.6; p < 0.01), personal care (r = 0.7; p < 0.01), pain and discomfort (r = 0.6; p < 0.01) and habitual activities (r = 0.6; p < 0.01), suggesting an association between albuminuria reduction and the impact of VD supplementation on HRQoL. CONCLUSION: Our data showed that high doses of cholecalciferol supplementation can improve HRQoL in patients with T1DM, and the reduction of albuminuria seems to be an important factor in this context. Trial registration: (ISRCTN32601947), 03/06/2017 retrospectively registered.
format Online
Article
Text
id pubmed-8959789
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89597892022-03-29 Health-related quality of life in T1DM patients after high-dose cholecalciferol supplementation: data from a pilot clinical trial de Souza, Ana Carolina Contente Braga de Oliveira, Maria Clara Neres Iunes de Lemos, Gabriela Nascimento da Silva, Emanuele Rocha de Souza, Ícaro José Araújo da Silva, Wanderson Maia de Alcântara, Angélica Leite Said, Nivin Mazen de Moraes, Lorena Vilhena Neto, João Felício Abrahão dos Passos, Simone Rodrigues Monteiro, Ádria Aline Alves de Queiroz, Natércia Neves Marques de Melo, Franciane Trindade Cunha Felício, Karem Miléo de Souza D’Albuquerque Silva, Lilian Gomes, Daniela Lopes Mourão, Neyla Arroyo Lara Piani, Pedro Paulo Freire Lobato, Isabel Jane Campos Felício, João Soares Diabetol Metab Syndr Research BACKGROUND: Type 1 Diabetes Mellitus (T1DM) impacts health-related quality of life (HRQoL). Cross-sectional studies suggest that low levels of vitamin D (VD) may impair HRQoL, however, the effect of VD supplementation on quality of life in T1DM patients has not yet been clarified. Our study evaluated the effects of high-dose VD supplementation on HRQoL in T1DM. METHODS: We performed a prospective study with 64 patients receiving cholecalciferol (4000 IU/day for patients with 25-OH-vitamin D [25(OH)D] between 30 and 60 ng/mL, and 10,000 IU/day for those with 25(OH)D below 30 ng/mL) for 12 weeks, as part of a research protocol. HRQoL was assessed with EuroQol instruments (EQ-5D and EQ-VAS). RESULTS: There was an improvement in global EQ-5D index, and analysing specifically the EQ-5D domains, we observed an improvement in mobility (1.3 ± 0.6 versus 1.1 ± 0.3, p < 0.01). Evaluating possible outcome influencing variables, we detected a reduction in albuminuria at the end of the trial, without changes in BMI, lipids, blood pressure, glycemic control and insulin doses. We found correlations between final albuminuria and the dimensions: mobility (r = 0.6; p < 0.01), personal care (r = 0.7; p < 0.01), pain and discomfort (r = 0.6; p < 0.01) and habitual activities (r = 0.6; p < 0.01), suggesting an association between albuminuria reduction and the impact of VD supplementation on HRQoL. CONCLUSION: Our data showed that high doses of cholecalciferol supplementation can improve HRQoL in patients with T1DM, and the reduction of albuminuria seems to be an important factor in this context. Trial registration: (ISRCTN32601947), 03/06/2017 retrospectively registered. BioMed Central 2022-03-28 /pmc/articles/PMC8959789/ /pubmed/35346321 http://dx.doi.org/10.1186/s13098-022-00817-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
de Souza, Ana Carolina Contente Braga
de Oliveira, Maria Clara Neres Iunes
de Lemos, Gabriela Nascimento
da Silva, Emanuele Rocha
de Souza, Ícaro José Araújo
da Silva, Wanderson Maia
de Alcântara, Angélica Leite
Said, Nivin Mazen
de Moraes, Lorena Vilhena
Neto, João Felício Abrahão
dos Passos, Simone Rodrigues
Monteiro, Ádria Aline Alves
de Queiroz, Natércia Neves Marques
de Melo, Franciane Trindade Cunha
Felício, Karem Miléo
de Souza D’Albuquerque Silva, Lilian
Gomes, Daniela Lopes
Mourão, Neyla Arroyo Lara
Piani, Pedro Paulo Freire
Lobato, Isabel Jane Campos
Felício, João Soares
Health-related quality of life in T1DM patients after high-dose cholecalciferol supplementation: data from a pilot clinical trial
title Health-related quality of life in T1DM patients after high-dose cholecalciferol supplementation: data from a pilot clinical trial
title_full Health-related quality of life in T1DM patients after high-dose cholecalciferol supplementation: data from a pilot clinical trial
title_fullStr Health-related quality of life in T1DM patients after high-dose cholecalciferol supplementation: data from a pilot clinical trial
title_full_unstemmed Health-related quality of life in T1DM patients after high-dose cholecalciferol supplementation: data from a pilot clinical trial
title_short Health-related quality of life in T1DM patients after high-dose cholecalciferol supplementation: data from a pilot clinical trial
title_sort health-related quality of life in t1dm patients after high-dose cholecalciferol supplementation: data from a pilot clinical trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959789/
https://www.ncbi.nlm.nih.gov/pubmed/35346321
http://dx.doi.org/10.1186/s13098-022-00817-w
work_keys_str_mv AT desouzaanacarolinacontentebraga healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT deoliveiramariaclaraneresiunes healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT delemosgabrielanascimento healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT dasilvaemanuelerocha healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT desouzaicarojosearaujo healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT dasilvawandersonmaia healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT dealcantaraangelicaleite healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT saidnivinmazen healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT demoraeslorenavilhena healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT netojoaofelicioabrahao healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT dospassossimonerodrigues healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT monteiroadriaalinealves healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT dequeiroznatercianevesmarques healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT demelofrancianetrindadecunha healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT feliciokaremmileo healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT desouzadalbuquerquesilvalilian healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT gomesdanielalopes healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT mouraoneylaarroyolara healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT pianipedropaulofreire healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT lobatoisabeljanecampos healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial
AT feliciojoaosoares healthrelatedqualityoflifeint1dmpatientsafterhighdosecholecalciferolsupplementationdatafromapilotclinicaltrial